Volume 11.29 | Aug 2

Cell Therapy News 11.29, August 2, 2010.
In this issue:  Science  |  Policy  |  Business  |  NIH  |  CBER  |  Regulatory  |  Events Subscribe  |  Unsubscribe


Researchers Make Progress Toward Regenerating Tissue to Replace Joints
Researchers have successfully regenerated rabbit joints using a cutting edge process to form the joint in vivo. In the study, bioscaffolds were infused with transforming growth factor beta 3 to promote growth of the rabbit joint. [Press release from the National Institutes of Health discussing online prepublication in The Lancet]

Animal Protein-Free
Feeder-Independent Maintenance Medium for hESCs & hiPSCs

by STEMCELL Technologies


Genetic Variations Responsible for High Triglyceride Levels
Researchers have shown that a combination of both common and rare variants in several genes add up and put a patient at risk of developing hypertriglyceridemia. [Press release from the University of Western Ontario discussing online prepublication in Nature Genetics]

Researchers Identify Key Enzyme in DNA Repair Pathway
Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer. [Press release from the University of Texas MD Anderson Cancer Center discussing online prepublication in Science]

Scientists Find Cell of Origin for Human Prostate Cancer
Researchers proved that basal cells found in benign prostate tissue could become human prostate cancer in mice with suppressed immune systems, a finding that bucks conventional wisdom. [Press release from the University of California, Los Angeles discussing online prepublication in Science]

Aging Cells Lose Protein Pumps
A family of proteins that pump molecules across the cell membrane may help to explain why yeast cells, and perhaps the cells of other organisms, are not able to go on producing copies of themselves forever. The same proteins may also partly explain how stem and cancer cells keep dividing. [Press release from NatureNews discussing online prepublication in Nature Cell Biology]

Obscure Immune Cells Thwart Ticks
A study now shows that basophils help repel bloodthirsty ticks that can spread lethal diseases. The work also introduces a new method for teasing out further immune functions of the often-overlooked cells. [Press release from ScienceNow discussing online prepublication in The Journal of Clinical Investigation]

Scientists Discover Cancer-Causing Gene — Helping to Distinguish Lung Cancer Subtypes
Scientists have identified a cancer-causing gene, BRF2, specific to squamous lung cell carcinoma. [Press release from the British Columbia Cancer Agency discussing online prepublication in PLoS Medicine]

Revolutionary Findings Prove Novel Mechanism of Stem Cells
Researchers show that bone marrow cells not only turn into new heart muscle themselves but also stimulate the body’s own cardiac stem cells to go into overdrive to contribute to the repair process. [Press release from the University of Miami Miller School of Medicine discussing online prepublication in Circulation Research]

Scientists 'Reprogram' Mouse Fat Cells into Clinically Useful Stem Cells
Scientists from the Monash Institute of Medical Research have “reprogrammed” adult mouse fat cells and neural cells to become induced pluripotent stem cells. [Press release from EurekAlert! discussing online prepublication in Cell Transplantation]

RNA Offers a Safer Way to Reprogram Cells
Researchers have shown, for the first time, that they can deliver reprogramming genes using RNA. This method could prove much safer than DNA-based reprogramming. [Press release from Massachusetts Institute of Technology discussing online prepublication in PLoS One]

Toxic Trio Identified as the Basis of Celiac Disease
Scientists have identified the three protein fragments that make gluten toxic to people with celiac disease. [Press release from the Walter and Eliza Hall Institute of Medical Research discussing online prepublication in Science Translational Medicine]

Therapeutic HIV Vaccines Show Promise
Researchers presented the results of a handful of successful, but small, early-phase clinical trials for therapeutic vaccines — once thought to be a dead end for tackling HIV. [Press release from NatureNews discussing research presented at the XVIII International AIDS 2010 Conference]

Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Geron Corporation announced that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed. [Geron Corporation Press Release]

Athersys Announces Positive Results from Phase I Study of Multistem® in Heart Attack Patients
Athersys, Inc. announced positive results from its Phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction. [Athersys, Inc. Press Release]

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Excess of Rare Variants in Genes Identified by Genome-Wide Association Study of Hypertriglyceridemia
Through genome-wide association studies, researchers identified common variants in APOA5GCKR, LPL and APOB associated with hypertriglyceridemia. [Nat Genet]

Regeneration of the Articular Surface of the Rabbit Synovial Joint by Cell Homing: A Proof of Concept Study
Researchers tested the hypothesis that the articular surface of the synovial joint can regenerate with a biological cue spatially embedded in an anatomically correct bioscaffold. [Lancet]

FAN1 Acts with FANCI-FANCD2 to Promote DNA Interstrand Cross-Link Repair
Researchers characterized a previously unrecognized nuclease, Fanconi anemia-associated nuclease 1 (FAN1), that promotes interstrand cross-linking repair in a manner strictly dependent on its ability to accumulate at or near sites of DNA damage and that relies on monoubiquitylation of the FANCI-FANCD2 complex. [Science]

Identification of a Cell of Origin for Human Prostate Cancer
Researchers show that basal cells from primary benign human prostate tissue can initiate prostate cancer in immunodeficient mice. [Science]

Asymmetrically Inherited Multidrug Resistance Transporters Are Recessive Determinants in Cellular Replicative Aging
Mutants lacking certain multidrug resistance (MDR) genes exhibited a reduced replicative lifespan (RLS), whereas introduction of only one extra copy of these MDR genes extended RLS. [Nat Cell Biol]

Selective Ablation of Basophils in Mice Reveals Their Nonredundant Role in Acquired Immunity Against Ticks
Data provide the first clear evidence that basophils play an essential and nonredundant role in antibody-mediated acquired immunity against ticks, which may suggest new strategies for controlling tick-borne diseases. [J Clin Invest]

Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma
Data suggest that genetic activation of BRF2 represents a unique mechanism of squamous cell carcinoma lung tumorigenesis through the increase of RNA polymerase III-mediated transcription. [PLoS Medicine]

Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation
Mesenchymal stem cells stimulate host cardiac stem cells, a new mechanism of action underlying successful cell-based therapeutics. [Circ Res]

The Efficient Generation of Induced Pluripotent Stem (iPS) Cells from Adult Mouse Adipose Tissue-Derived and Neural Stem Cells
Findings confirm that adipose tissue-derived cells are an ideal candidate as a readily accessible somatic cell type for high efficiency establishment of iPS cell lines. [Cell Transplant]

Innate Immune Suppression Enables Frequent Transfection with RNA Encoding Reprogramming Proteins
Researchers show that combined knockdown of interferon-beta (Ifnb1), Eif2ak2, and Stat2 rescues cells from the innate immune response triggered by frequent long-RNA transfection. Using this technique, they were able to transfect primary human fibroblasts every 24 hours with RNA encoding the reprogramming proteins Oct4, Sox2, Klf4, and Utf1. [PLoS One]

Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease
Findings show that pathogenic T cells in celiac disease show limited diversity, and therefore suggest that peptide-based therapeutics for this disease and potentially other strongly HLA-restricted immune diseases should be possible. [Sci Transl Med]

The most published medium for hematopoietic CFC assays

by STEMCELL Technologies


NSF Funding Request Faring Well in Congress
While the 2011 budget requests of other U.S. research agencies are struggling to stay afloat in choppy fiscal seas, so far National Science Foundation’s (NSF) is sailing through Congress largely intact. [National Science Foundation, United States]

Obama, Clinton Pledge U.S. Support for AIDS Fight
President Barack Obama and Secretary of State Hillary Rodham Clinton have pledged the support of the United States in the global fight against AIDS. [Department of State, United States]

Agency Information Collection Activities: Proposed Collection; Comment Request [Agency for Healthcare Research and Quality, United States]



STEMCELL Technologies Applauds Nature Protocol Article Published by Prominent HIV Lab at the Institut Pasteur Citing the Use of RoboSep® to Isolate CD4+ and CD8+ T Cells
In a recent, high-impact Nature Protocol publication, Asier Sáez-Cirión and his group at the Institut Pasteur standardized the protocol for T cell-based HIV suppression. RoboSep®, the fully automated cell separator from STEMCELL Technologies, was the instrument of choice for cell isolation procedures. [STEMCELL Technologies Inc. Press Release]

Sanofi-aventis Said to be Likely to Bid $18 Billion for Genzyme
Sanofi-aventis is likely to make an unsolicited offer of up to $70 a share for Genzyme, raising the stakes for what could become one of the year’s biggest deals, people briefed on the matter said. [The New York Times]

Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology Through 2023
Regeneron Pharmaceuticals, Inc. and Astellas Pharma Inc. announced that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune® technology in its internal research programs to discover fully human monoclonal antibody product candidates. [Regeneron Pharmaceuticals, Inc. Press Release]

Charles River Announces Mutual Termination of Acquisition Agreement with WuXi PharmaTech
Charles River Laboratories International, Inc. announced that it has mutually agreed with WuXi PharmaTech Inc. to terminate their previously announced acquisition agreement. [Charles River Laboratories International, Inc. Press Release]

Canadian Researchers Testing Unique Vaccines for Prion Diseases and Common Cancers
Several Canadian researchers have come together to help control the relentless spread chronic wasting disease in deer and elk through vaccines and to generate safe and effective therapies for common cancers. The multi-provincial research involves three scientists along with two industry partners, Amorfix Life Sciences Ltd. and PREVENT, the Pan Provincial Vaccine Initiative. [PrioNet Canada Press Release]

British Companies to Receive Support to Develop New Regenerative Medicine Products and Technologies
The government-backed Technology Strategy Board is to invest over £5 million to support the research and development in the UK of new regenerative medicine products, tools and technologies. 16 research and development projects in the field of regenerative medicine therapeutics are to receive a total of £3.6 million of investment, while a further £1.6 million is to be invested in 12 feasibility studies in the area of regenerative medicine tools and technologies. [Technology Strategy Board Press Release]

Cerenis Therapeutics Raises EUR40 Million in Series C Financing
Cerenis Therapeutics SA announced it has raised EUR40 million in the first close of its series C financing. [Cerenis Therapeutics SA Press Release]

Immune Design Corporation Raises $32 Million in Series B Financing
Immune Design Corporation announced that it has secured $32 million in Series B financing. [PR Newswire]

Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair
Cytori Therapeutics received expanded European approval for its Celution® System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. [Cytori Therapeutics Press Release]

FDA Grants Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID®, Targeting Mantle Cell Lymphoma
Biovest International, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. [Biovest International, Inc. Press Release]

Oxford BioMedica Announces FDA Approval for TroVax® Phase II Study in Prostate Cancer
Oxford BioMedica announced that it has received approval from the U.S. Food and Drug Administration (FDA) and Recombinant DNA Advisory Committee to initiate a clinical Phase II study in the United States to assess the activity of TroVax® (MVA-5T4) in patients with progressive hormone refractory prostate cancer. [Oxford BioMedica Press Release]


Senate Spending Panel Approves $1 Billion Boost for NIH
A Senate subcommittee matched President Barack Obama's request for a $1 billion increase in 2011 for the National Institutes of Health (NIH). That raise would bring the agency's total budget to $32 billion, or 3.5% above the 2010 level, according to a statement from the Senate appropriations labor, health, and human services subcommittee. [National Institutes of Health, United States]

NIH Takes on New Role in Fight Against Rare Diseases
A government program focusing on rare diseases, the Therapeutics for Rare and Neglected Diseases (TRND) program, has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs. TRND will work together with scientists, advocates and others to do the required research and testing on drugs before a compound can be tried in humans in a clinical trial. [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (Doc. 2010-18627)

National Cancer Institute; Notice of Closed Meetings

Office of the Director; Notice of Closed Meeting

National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting

Request for Proposals (RFP): NIA Intervention Testing Program Solicits Proposals for Compounds to Test for Anti-Aging Activity in Mice (NOT-AG-10-008)

Viral and Host Genetic Factors Regulating HIV-Associated CNS Disease (R01) (RFA-MH-11-020)

Request for Information (RFI): Ideas for Improvements in a Research Network to Advance the Treatment Science of Critically Ill Patients with Acute Lung Injury (NOT-HL-11-113)

Correction of Major Programmatic Priorities for RFA-HL-11-025 (R01); “New Strategies for Growing 3D Tissues” (NOT-HL-11-115)



Influenza Virus Vaccine for the 2010-2011 Season

Cytokines 2010 645x110



Risk Evaluation and Mitigation Strategy (REMS) Public Meeting
The Food and Drug Administration announced a 2-day public meeting to obtain input on issues and challenges associated with the development and implementation of risk evaluation and mitigation strategies for drugs. An archived webcast of the meeting is available.


MHRA Business Plan 2010 and Corporate Plan 2010-15 Published
The MHRA gained ministerial agreement for the Agency's Business Plan 2010 and the Corporate Plan 2010-15.

Regulation of Advanced Therapy Medicinal Products in the UK
The statutory instrument for implementing the UK's requirements under the hospital exemption scheme (The Medicines for Human Use (Advanced Therapy Medicinal Products and Miscellaneous Amendments) Regulations 2010) was laid in Parliament on 26 July 2010.

EVENTS (Listed by Date)

NEW XXIII International Congress of the Transplantation Society
August 15-19, 2010
Vancouver, Canada

CHI's 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS)
August 17-19, 2010
Cambridge, United States

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences 2nd Annual World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Viral Vectors in Gene Therapy: Applications and Novel Production Methods
August 26-September 4, 2010
Kuopio, Finland

NEW European Workshop on Skin Stem Cells
August 31-September 2, 2010
Cambridge, United Kingdom

Clinical Trials International Summit 2010
September 1-2, 2010
Shanghai, China

NEW Third Annual Limbal Stem Cell Meeting
September 10, 2010
Reading, United Kingdom

International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Hydra VI: The European Summer School on Stem Cells & Regenerative Medicine
September 11-17, 2010
Hydra, Greece

Joint Metastasis Research Society – American Association of Cancer Research Conference on Metastasis and the Tumor Microenvironment
September 12-15, 2010
Philadelphia, United States

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Select Biosciences 7th Annual RNAi & miRNA Europe
September 14-15, 2010
Dublin, Ireland

Select Biosciences Inaugural Epigenetics Europe Conference
September 14-15, 2010
Dublin, Ireland

Select Biosciences Inaugural Genomics Automation Europe Conference
September 14-15, 2010
Dublin, Ireland

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

NEW First Annual BIO India International Partnering Conference
September 21-22, 2010
Hyderabad, India

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

NEW International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress
September 27-29, 2010
Doha, Qatar

4th American Association of Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development
September 27-30, 2010
Denver, United States

Select Biosciences 6th Annual Ion Channel Targets Conference
September 28-29, 2010
Washington, DC, United States

Cytokines 2010: Cytokines in Infectious Diseases, Autoimmune Disorders and Cancer
October 3-7, 2010
Chicago, United States

2010 World Stem Cell Summit
October 4-6, 2010
Detroit, United States

5th World Congress on Preventive & Regenerative Medicine (WCRM)
October 5-7, 2010
Hannover, Germany

17th Annual Meeting German Society for Gene Therapy (DG-GT e.V.)
October 6-9, 2010
Munich, Germany

COGEM Symposium: GM Viruses as Medicine: Panacea or Pandora's Box?
October 7, 2010
Amsterdam, The Netherlands

American Association of Blood Banks (AABB) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

NEW 18th Annual BioPartnering Europe
October 10-12, 2010
London, United Kingdom

NEW New York Stem Cell Foundation Fifth Annual Translational Stem Cell Research Meeting
October 12-13, 2010
New York, United States

Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

NEW 2010 NanoMedicine Summit
October 18-19, 2010
Cleveland, United States

European Society of Gene and Cell Therapy (ESGCT) 18th Annual Congress
October 22-25, 2010
Milan, Italy

3rd Annual Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM)
October 26-27, 2010
Dubai, United Arab Emirates

World Stem Cells & Regenerative Medicine Congress Asia 2010
October 26-29, 2010
Singapore City, Singapore

Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

Fraunhofer Life Science Symposium 2010
October 29-30, 2010
Leipzig, Germany

Stem Cell Society Singapore Symposium 2010: Translating Science to Therapy
November 2-3, 2010
Singapore City, Singapore

World Cord Blood Congress
November 4-7, 2010
Marseille, France

Select Biosciences 5th Annual European Biomarkers Summit
November 9-10, 2010
Florence, Italy

Select Biosciences International Forum on Stem Cells
November 12-13, 2010
Tianjin, China

Select Biosciences 2nd Annual RNAi Asia Conference
November 15-16, 2010
Singapore City, Singapore

9th Annual Gene Therapy Symposium for Heart, Lung, and Blood Diseases
November 17-19, 2010
Sonoma, United States

NEW 8th Annual Commercial Translation of Regenerative Medicine Conference
November 18-19, 2010
London, United Kingdom

Stem Cell Network 10th Annual Scientific Meeting
November 22-24, 2010
Calgary, Canada

NEW HealthTech and Medicines Knowledge Transfer Network 7th Annual BioProcessUK Conference
November 24-25, 2010
Manchester, United Kingdom

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference
December 5-8, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

Phacilitate 7th Annual Cell & Gene Therapy Forum 2011
January 24-26, 2011
Washington DC, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.



Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization's career opportunities with Cell Therapy News.
here to post your career opportunities.

Comments or Suggestions? Email [email protected] with your feedback.

 Learn more about Cell Therapy News:  Archives  |  Events  |  Update Profile  |  Contact Us